CA3258968A1 - PHARMACEUTICAL COMPOSITION CONTAINING PIMITESPIB - Google Patents

PHARMACEUTICAL COMPOSITION CONTAINING PIMITESPIB

Info

Publication number
CA3258968A1
CA3258968A1 CA3258968A CA3258968A CA3258968A1 CA 3258968 A1 CA3258968 A1 CA 3258968A1 CA 3258968 A CA3258968 A CA 3258968A CA 3258968 A CA3258968 A CA 3258968A CA 3258968 A1 CA3258968 A1 CA 3258968A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
crystalline cellulose
tablet
granulated product
manufactured
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3258968A
Other languages
English (en)
French (fr)
Inventor
Tetsuya Nishiyama
Yuuichirou NIKI
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of CA3258968A1 publication Critical patent/CA3258968A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3258968A 2022-06-10 2023-06-09 PHARMACEUTICAL COMPOSITION CONTAINING PIMITESPIB Pending CA3258968A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022094420 2022-06-10
JP2022-094420 2022-06-10
PCT/JP2023/021535 WO2023238929A1 (ja) 2022-06-10 2023-06-09 ピミテスピブを含有する医薬組成物

Publications (1)

Publication Number Publication Date
CA3258968A1 true CA3258968A1 (en) 2025-04-18

Family

ID=89118411

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3258968A Pending CA3258968A1 (en) 2022-06-10 2023-06-09 PHARMACEUTICAL COMPOSITION CONTAINING PIMITESPIB

Country Status (10)

Country Link
US (1) US20250312280A1 (https=)
EP (1) EP4537824A1 (https=)
JP (1) JPWO2023238929A1 (https=)
KR (1) KR20250022143A (https=)
CN (1) CN119365195A (https=)
AU (1) AU2023282693A1 (https=)
CA (1) CA3258968A1 (https=)
MX (1) MX2024015327A (https=)
TW (1) TW202404585A (https=)
WO (1) WO2023238929A1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4608087B2 (ja) * 1999-12-22 2011-01-05 富山化学工業株式会社 固形製剤の製造法
PT2452940E (pt) 2009-07-10 2015-02-27 Taiho Pharmaceutical Co Ltd Composto azabiciclo e seu sal
EP2498759B1 (en) * 2009-11-13 2018-08-01 AstraZeneca AB Immediate release tablet formulations
MX353289B (es) * 2011-05-25 2018-01-05 Taiho Pharmaceutical Co Ltd Tableta revestida en seco que contiene tegafur, gimeracil y oteracil potasico.
RU2657783C2 (ru) 2013-09-30 2018-06-15 Тайхо Фармасьютикал Ко., Лтд. Комбинированная терапия с использованием азабициклосоединения для ракового заболевания
JP6537601B2 (ja) 2015-05-12 2019-07-03 大鵬薬品工業株式会社 アザ二環式化合物の結晶
DK3646869T3 (da) 2017-06-30 2025-09-15 Taiho Pharmaceutical Co Ltd Kemoterapi mod kræft under anvendelse af azabicycloforbindelse
BR112020005100A2 (pt) 2017-09-15 2020-09-15 Taiho Pharmaceutical Co., Ltd. usos de um composto inibidor de hsp90 para produzir um agente profilático e/ou terapêutico para doenças que envolvem expressão de ido e para produzir uma composição farmacêutica para tratar tumores ido-positivos
JP6918204B2 (ja) * 2018-03-19 2021-08-11 大鵬薬品工業株式会社 アルキル硫酸ナトリウムを含む医薬組成物
AU2018423606B2 (en) 2018-05-14 2024-10-10 Taiho Pharmaceutical Co., Ltd. Method of treating malignant tumor by azabicyclic compound

Also Published As

Publication number Publication date
EP4537824A1 (en) 2025-04-16
TW202404585A (zh) 2024-02-01
CN119365195A (zh) 2025-01-24
KR20250022143A (ko) 2025-02-14
WO2023238929A1 (ja) 2023-12-14
US20250312280A1 (en) 2025-10-09
MX2024015327A (es) 2025-02-10
AU2023282693A1 (en) 2025-01-02
JPWO2023238929A1 (https=) 2023-12-14

Similar Documents

Publication Publication Date Title
KR101840182B1 (ko) 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일]-1ｈ-퀴놀린-2-온 락테이트 일수화물을 포함한 제약 조성물
EP3769765B1 (en) Pharmaceutical composition including sodium alkyl sulfate
US20230203009A1 (en) Pralsetinib pharmaceutical compositions
JP2022532540A (ja) アキシチニブを含有する医薬組成物
TW200808358A (en) Galenical formulations of organic compounds
EP3886817A1 (en) Pharmaceutical composition comprising ramipril and indapamide
US20250312280A1 (en) Pharmaceutical composition containing pimitespib
JP7585043B2 (ja) レナリドミドを含む医薬組成物
RU2857663C2 (ru) Фармацевтическая композиция, содержащая пимитеспиб
TW202408531A (zh) 包含葡萄糖酸內酯之哌柏西利製劑
WO2019076966A1 (en) TABLETS COMPRISING TAMSULOSIN AND SOLIFENACIN
HK40115959A (zh) 含有匹米替比的医药组合物
US20120121722A1 (en) Atazanavir formulations
TWI878600B (zh) 用於治療或預防高血壓及高膽固醇血症之單一劑型的醫藥組成物
JP2014070061A (ja) シクロデキストリンとの混合体を含有する錠剤
EP4282415A1 (en) A stable tablet composition of axitinib
CA3237792A1 (en) Pharmaceutical composition having excellent dissolution properties
HK40109685A (en) Pharmaceutical composition having excellent elution property
KR20250048897A (ko) 용해도 및 안정성이 개선된 팔보시클립을 포함하는 약학 조성물
JP2025018790A (ja) トファシチニブを含有するフィルムコーティング錠剤
JP2018020968A (ja) ゲフィチニブを有効成分とする医薬組成物
JP2026065171A (ja) イストラデフィリン含有口腔内崩壊錠
EP4295839A1 (en) Combination of valsartan and indapamide
JP2021070658A (ja) アビラテロン酢酸エステル含有製剤
JP2021070659A (ja) アビラテロン酢酸エステル含有製剤

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241210

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241210

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241210

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241210

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250312

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250312

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250312

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250312

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250321

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250321

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250321

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250321

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250321

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250321

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-2-2-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION)

Effective date: 20250418

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250513

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250513

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251211